For research use only. We do not sell to patients.
Ionizable lipids / DLin-MC3-DMA
DLin-MC3-DMA chemical structure
Product imageResearch use only
CAT. NO. DC10800Featured

DLin-MC3-DMA

Pack size & price

USD
TotalUS$250
We match the best price and quality on market.
Ships from ShanghaiIce-pack transportPure lipid recommended

DLin-MC3-DMA (MC3) is an ionizable lipid studied for hepatic siRNA delivery. The 2012 study reported formulation-dependent Factor VII silencing in mice and transthyretin silencing in cynomolgus monkeys. Initial and optimized lipid compositions are documented separately.

Open full Formulation & Performance →

Literature evidence · DC10800

Formulation & Performance

MC3 potency depends on the complete lipid composition. The initial screening formulation and the optimized animal formulation have different PEG-lipid proportions and different ED50 values.

MC3 is lipid 16 in Jayaraman et al. The product molecular weight is 642.11. The LNP apparent pKa of 6.44 is a formulation measurement, not a molecular-weight or purity specification.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
DLin-MC3-DMADC10800642.11400.256844
DSPCDC57005790.15100.079015
CholesterolDCD-041386.65400.154660
PEG-C18 carbamateNot uniquely mappedNot established10Not calculable from disclosed data

Initial screen: MC3/DSPC/cholesterol/PEG-C18 carbamate = 40:10:40:10 mol%. The source reports siRNA/total lipid = 0.05 by mass, equivalent to total lipid/siRNA = 20:1. This is not an N/P ratio. The PEG component is not DMG-PEG2000; its catalog mapping and molecular weight remain unassigned.

Component mass calculator

Not all inputs are assigned to a single verified study formulation; unassigned fields are blank. Enter your own values to calculate a research scenario. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
DLin-MC3-DMA——
DSPC——
Cholesterol——
PEG-C18 carbamate——

Optimized animal formulation

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
DLin-MC3-DMADC10800642.11500.321055
DSPCDC57005790.15100.079015
CholesterolDCD-041386.6538.50.148860
PEG-lipid; precise identity pending SI verificationNot uniquely mappedNot established1.5Not calculable from disclosed data

Optimized MC3/DSPC/cholesterol/PEG-lipid = 50:10:38.5:1.5 mol%. The main text supplies the proportions but does not independently establish the optimized PEG identity in this review. The screening formulation PEG molecular weight is not carried over.

Component mass calculator

Not all inputs are assigned to a single verified study formulation; unassigned fields are blank. Enter your own values to calculate a research scenario. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
DLin-MC3-DMA——
DSPC——
Cholesterol——
PEG-lipid; precise identity pending SI verification——

Formulation identity and physicochemical context

Study / conditionResultInterpretation
Apparent ionizationMC3-containing LNP pKa 6.44Reported for the study LNP; not an intrinsic constant under all conditions.
Initial screening LNPs40:10:40:10; RNA/total lipid 0.05 by massThis formulation generated the 0.03 mg/kg mouse ED50.
Screen-wide particle characterization70–90 nm; PDI 0.11 ± 0.04 across the screened libraryPooled library description, not a batch specification for MC3.

Jayaraman et al., main text, Table 1 and Figs. 4–5.

Mouse Factor VII silencing: initial screen

Study / conditionResultInterpretation
EndpointCirculating Factor VII protein after FVII siRNA deliveryGene silencing, not reporter mRNA expression.
MC3 / lipid 16ED50 0.03 mg siRNA/kg in the 40:10:40:10 formulationDose producing approximately 50% silencing in this model.
Structure comparisonThe MC3 pKa region coincided with high potency in the tested seriesThis association does not make pKa alone a universal predictor.

Main Table 1 and Figs. 4–5. Dose units refer to siRNA, not lipid mass.

Mouse Factor VII silencing: optimized composition

Study / conditionResultInterpretation
50:10:38.5:1.5 formulationED50 0.005 mg siRNA/kgSixfold lower ED50 than the initial MC3 composition.
Comparison basisSame named ionizable lipid; changed helper-lipid proportionsThe optimized ED50 must not be assigned to the initial screen recipe.
Figure reportingDose-response inset in Fig. 7; n = 5, mean ± SDThe graph supports a formulation-specific potency statement.

Main text and Fig. 7 inset.

Non-human primate hepatic delivery

Study / conditionResultInterpretation
Model and administrationCynomolgus monkeys; TTR siRNA; 15-minute intravenous infusionOptimized 50:10:38.5:1.5 lipid composition.
Doses0.03, 0.1 and 0.3 mg siRNA/kgDifferent target and species from the mouse FVII experiment.
OutcomeTTR silencing ED50 <0.03 mg/kg; n = 3 per groupSupports primate hepatic siRNA delivery; does not establish mRNA or extrahepatic performance.

Main Fig. 7. Detailed time-point verification remains pending the complete supporting information.

Scope of biological and safety evidence

Study / conditionResultInterpretation
Mixed-lipid experimentFVII measured 24 h after 0.1 mg siRNA/kg in Fig. 6Ionization and delivery activity were examined using mixtures of related lipids.
Safety interpretationThis article is primarily a delivery-potency studyDo not infer a chronic toxicity margin or human dosing recommendation.
Translation limitsFVII and TTR are distinct hepatic endpointsA single ED50 cannot summarize every MC3 formulation, RNA payload or route.

Main Figs. 6–7. Complete SI retrieval was unsuccessful; missing PEG identity and detailed assay conditions are left unresolved.

Original study figures

Mouse and primate dose-response curves — Figure 7 — Original source figures.

Ionization and silencing comparisons — Figures 5–6 — Original source figures.

References and source locations

  1. Jayaraman M et al. Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo. Angew Chem Int Ed 51, 8529–8533 (2012). DOI: 10.1002/anie.201203263
CAS No.1224606-06-7
Chemical NameDLin-MC3-DMA
SynonymsDLinMC3DMA， DLin MC3 DMA
SMILESCCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC
FormulaC43H79NO2
M.Wt642.11
Purity>95% by ELSD-HPLC
StoragePure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping conditionShips from Shanghai. Pure lipid is stable during ice-pack transport.
Publication
  1. Jayaraman M et al. Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo. Angew Chem Int Ed 51, 8529–8533 (2012). DOI: 10.1002/anie.201203263
Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Mass = concentration × volume × molecular weight
Enter any three values to calculate the fourth.
C₁V₁ = C₂V₂
Enter any three values to calculate the fourth.
Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass1 mM5 mM10 mM
10 mg15.5858 mL3.1172 mL1.5586 mL
25 mg38.9645 mL7.7929 mL3.8964 mL
50 mg77.9290 mL15.5858 mL7.7929 mL
100 mg155.8579 mL31.1716 mL15.5858 mL
250 mg389.6448 mL77.9290 mL38.9645 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Contact us
Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?
We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.
Pure lipid or solution — which should I choose?
Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.
How should I measure a small amount of oily or viscous lipid?
Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.
Can you support formulation optimization and scale-up?
Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.